NUVALENT, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 69.22 USD | -1.61% |
|
+1.80% | -6.01% |
| May. 01 | Nuvalent Insider Sold Shares Worth $2,666,555, According to a Recent SEC Filing | MT |
| Apr. 17 | Nuvalent Insider Sold Shares Worth $2,458,335, According to a Recent SEC Filing | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | 7.98M | Capitalization | 4.54B |
|---|---|---|---|---|---|
| Net income 2024 * | -185M | Net income 2025 * | -220M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 569 x |
| P/E ratio 2024 * |
-24.2
x | P/E ratio 2025 * |
-20.9
x | Employees | 92 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.87% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -1.61% | ||
| 1 week | +1.80% | ||
| Current month | +0.42% | ||
| 1 month | +1.07% | ||
| 3 months | -12.81% | ||
| 6 months | +23.32% | ||
| Current year | -6.01% |
1 week
67.20
74.79
1 month
61.8074.79
Current year
61.8089.39
1 year
37.1389.39
3 years
7.0989.39
5 years
7.0989.39
10 years
7.0989.39
| Managers | Title | Age | Since |
|---|---|---|---|
James Porter
CEO | Chief Executive Officer | 48 | 16-12-31 |
Alexandra Balcom
DFI | Director of Finance/CFO | 40 | 20-12-31 |
Jeffrey Lee
CTO | Chief Tech/Sci/R&D Officer | - | 22-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 53 | 21-06-30 | |
Anna Protopapas
CHM | Chairman | 59 | 22-03-29 |
Andrew Hack
BRD | Director/Board Member | 50 | 21-05-10 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.12% | 0 M€ | 0.00% | - | |
| 0.07% | 0 M€ | 0.00% | - | |
| 0.01% | 773 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-06 | 69.25 | -1.56% | 170 811 |
| 24-05-03 | 70.35 | -2.95% | 346,463 |
| 24-05-02 | 72.49 | +2.60% | 325,740 |
| 24-05-01 | 70.65 | +2.57% | 533,982 |
| 24-04-30 | 68.88 | +1.37% | 477,196 |
Delayed Quote Nasdaq, May 06, 2024 at 03:39 pm EDT
More quotes
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases and drive more durable responses. It is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, NVL-520, is being developed for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, NVL-655, is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC. LC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
70.35
USD
Average target price
101.1
USD
Spread / Average Target
+43.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.01% | 4.54B | |
| +21.91% | 47.9B | |
| +46.56% | 41.42B | |
| -2.32% | 40.7B | |
| -6.20% | 28.92B | |
| +11.12% | 25.55B | |
| -21.78% | 19.27B | |
| -1.02% | 12.15B | |
| +30.46% | 12.14B | |
| -0.91% | 11.99B |
- Stock Market
- Equities
- NUVL Stock